


# PROVIDER NEWSLETTER

Important Information for Molina Healthcare Provider Networks

## First Quarter 2022



#### In this Issue

| Consumer Assessment of Healthcare Providers and Systems (CAHPS®)/Marketplace Qualified Health Plan (QHP) Enrollee Experience Survey |
|---|
| Molina Healthcare 2021 Quality Improvement Results  |
| Requirements for Submitting Prior Authorizations for Molina 5   |
| Strengthening the Primary Care<br>Setting with Trauma-Informed Care 6   |
| Secure Messaging from Claim Status<br>Screen Enabled in Availity Essentials<br>Portal6  |
| Clinician Administered Preferred Drug<br>List 20227   |

Consumer Assessment of Healthcare Providers and Systems (CAHPS®) / Marketplace Qualified Health Plan (QHP) Enrollee Experience Survey

The Consumer Assessment of Healthcare Providers and Systems (CAHPS®) / Marketplace Qualified Health Plan (QHP) Enrollee Experience Survey is an industry standard survey tool used to evaluate patient satisfaction. Improving patient satisfaction has many benefits. It not only helps to increase patient retention, but can also help increase compliance with physician recommendations and improve patient outcomes.

Focusing together on a positive patient experience will have many important benefits to your practice:

- Increase patient retention
- Increase compliance with physician clinical recommendations
- Improve patients' overall wellness and health outcomes
- Ensure preventive care needs are addressed more timely
- Reduce no-show rates

Additional resources are available for office staff and patients:

- For additional after-hours coverage, Molina Healthcare members can call the 24-Hour Nurse Advice Line
   English (888) 275-8750
   Spanish (866) 648-3537
- Molina Healthcare members can access Interpreter Services at no cost by calling Member Services (888) 999-2404.
- Providers can access the Provider Web Portal at provider. Molina Healthcare.com to:
  - Search for patients and check member eligibility
  - o Submit service request authorizations and/or claims and check status
  - o Review Patient Care Plan
  - Obtain CAHPS® Tip Sheets
  - Participate in online Cultural Competency trainings (also available at <u>MolinaHealthcare.com</u>, under Health Resources tab)

Please encourage your patients who have received the CAHPS®/QHP survey to participate. Listed below are several questions asked in the survey regarding patient care:

- When you needed care right away, how often did you get care as soon as you needed?
- When you made an appointment for a checkup or routine care at a doctor's office or clinic, how often did you get an appointment as soon as you needed?
- How often was it easy to get the care, tests and treatment you needed?
- How often did your personal doctor listen carefully to you?
- How often did your personal doctor spend enough time with you?
- How often did your personal doctor explain things in a way that was easy for you to understand?
- How often did you and your personal doctor talk about all the prescription medicines you were taking?
- How would you rate your personal doctor?

## Molina Healthcare 2021 Quality Improvement Results

Molina Healthcare conducts an annual program evaluation to assess how well we meet the performance goals and objectives for improving the quality and safety of clinical care and services specified within the Quality Improvement Program Description and Annual Work Plan. Below are highlights from the annual evaluation.

# **CAHPS®/QHP Enrollee Experience Survey**



The Consumer Assessment of Healthcare Providers and Systems (CAHPS®) / Marketplace Qualified Health Plan (QHP) Enrollee Experience Survey assesses Molina members' satisfaction with their health care. It allows us to better serve our members.

Molina has received the CAHPS®/QHP Enrollee Experience Survey results of how our members rated our providers and our services.

**Medicaid:** In 2021, Molina improved in the following CAHPS measures: Getting Needed Care, Coordination of Care, Rating of Health Care, Rating of Personal Doctor and Rating of Health Plan.

We need to make improvements in Getting Care Quickly, How Well Doctors Communicate, Customer Service/Plan Administration, and Rating of Specialist Seen Most Often.

**Medicare:** In 2021, Molina improved in the following CAHPS measures: Getting Care Quickly, Rating of Personal Doctor, Rating of Specialist Seen Most Often, Rating of Health Plan and Flu Vaccinations.

We need to make improvements in the CAHPS measure: Overall Rating of Drug Plan.

**Marketplace:** In 2021, Molina improved in the QHP Enrollee Experience Survey measure: Customer Service/Plan Administration.

We need to make improvements in the following QHP Enrollee Experience Survey measures: How Well Doctors Communicate, Coordination of Care, Rating of Health Care, Rating of Personal Doctor, Rating of Specialist Seen Most Often, Rating of Health Plan, Access to Care, Access to Information, Cultural Competence, Flu Vaccinations, Medical Assistance w/Smoking/Tobacco Use Cessation, Overall Rating of Drug Plan, and Getting Prescriptions Filled Easily.

#### **HEDIS®**

Another tool used to improve member care is the Healthcare Effectiveness Data and Information Set or HEDIS®. HEDIS® scores allow Molina to monitor how many members are receiving the services they need. Measures include immunizations, well-child exams, Pap tests and mammograms. There are also scores for diabetes care, and prenatal and afterdelivery care.

**Medicaid:** In 2021, Molina improved in Childhood Immunization Status (CIS) - Combination #10, Asthma Medication Ratio (AMR) - Total, Antidepressant Medication Management (AMM) - Effective Continuation Phase Treatment, Appropriate Treatment for Upper Respiratory Infection (URI) – Total.

Molina needs to make improvements in Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) - BMI Percentile, Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) - Counseling for Nutrition, Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) - Counseling for Physical Activity, Immunizations for Adolescents (IMA) - Combination #2, Breast Cancer Screening (BCS), Cervical Cancer Screening (CCS), Chlamydia Screening in Women (CHL) - Total, Appropriate Testing for Pharyngitis (CWP) - Total, Controlling High Blood Pressure (CBP), Comprehensive Diabetes Care (CDC) - HbA1c Control (<8.0%), Comprehensive Diabetes Care (CDC) - Eye Exam (Retinal) Performed, Comprehensive Diabetes Care (CDC) - Blood Pressure Control (<140/90 mm Hg), Follow-Up Care for Children Prescribed ADHD Medication (ADD) - Initiation Phase, Follow-Up Care for Children Prescribed ADHD Medication (ADD) - Continuation and Maintenance (C&M) Phase, Prenatal and Postpartum Care (PPC) - Timeliness of Prenatal Care and Prenatal and Postpartum Care (PPC) - Postpartum Care.

**Medicare:** In 2021, Molina improved in Colorectal Cancer Screening (COL), Care for Older Adults (COA) - Advance Care Planning, Statin Therapy for Patients with Cardiovascular Disease (SPC) - Total Received Statin Therapy and Statin Therapy for Patients with Cardiovascular Disease (SPC) - Total Statin Adherence 80%.

Molina needs to make improvements in Breast Cancer Screening (BCS), Care for Older Adults (COA) - Medication Review, Care for Older Adults (COA) - Functional Status Assessment, Care for Older Adults (COA) - Pain Assessment, Comprehensive Diabetes Care (CDC) - HbA1c Control (<8%), Comprehensive Diabetes Care (CDC) - Eye Exam (Retinal) Performed, Comprehensive Diabetes Care (CDC) - Medical Attention for Nephropathy and Controlling High Blood Pressure (CBP).

**Marketplace:** In 2021, Molina improved in Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) - BMI Percentile, Chlamydia Screening in Women (CHL) - Total, Comprehensive Diabetes Care (CDC) - HbA1c Control (<8.0%) and Prenatal and Postpartum Care (PPC) - Postpartum Care.

Molina needs to make improvements in Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) - Counseling for Nutrition, Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) - Counseling for Physical Activity, Cervical Cancer Screening (CCS), Controlling High Blood Pressure (CBP), Comprehensive Diabetes Care (CDC) - Eye Exam (Retinal) Performed, Comprehensive Diabetes Care (CDC) - Medical Attention for Nephropathy and Prenatal and Postpartum Care (PPC) - Timeliness of Prenatal Care.

#### **Culturally and Linguistically Appropriate Services/Disability Resources**

Molina also assesses the cultural, ethnic, racial and linguistic needs and preferences of members on an ongoing basis. Information gathered during regular monitoring and annual network assessment is used to identify and eliminate cultural and/or linguistic barriers to care through the implementation of programs and interventions.

**Medicaid:** Between January 1 and September 30, 2021, 1,819 interpreter services were requested by Molina of Wisconsin Medicaid members which represents 3% of the plan's Medicaid members and 22% of members whose preferred language is not English. Spanish was the top language requested by Medicaid members followed by Burmese and Rohingya. The top three languages requested among Medicaid members in 2020 were Spanish, Burmese and Karen. A significant year-over-year change in the top languages requested via interpreter services was not observed.

**Medicare:** The majority of Medicare members (88%) speak English as their preferred language. In 2021, 11% of Medicare members identified themselves as Spanish speakers, which is a 2% increase compared to the previous year. No other languages were spoken by 1% or more of members. Spanish was the most requested language among Medicare members through Molina's interpreter services, followed by Burmese and Laotian.

**Marketplace:** Between January 1 and September 30, 2021, 568 interpreter services were requested by Molina Healthcare of Wisconsin Marketplace members, which represents 2% of the plan's Marketplace members and 2% of members who preferred language is not English. Note: 93% of Marketplace members do not specify a preferred language. Spanish was the top language requested by Marketplace members followed by Mandarin and Vietnamese. The top three languages requested among Marketplace members in 2020 were

Spanish, Mandarin and Burmese. A significant year-over-year change in the top languages requested via interpreter services was not observed.

Overall, Molina found that the current Culturally and Linguistically Appropriate Services program resources, structure, and practitioner and community participation are sufficient based on member needs. Additionally, Molina has a series of short Culturally Competency training videos (Health Disparities, LGBTQ+, Immigrants/Refugees, etc.) available on the Provider Web Portal and at MolinaHealthcare.com on the Culturally and Linguistically Appropriate Resources/Disability Resources page listed under Health Resources. Disability resources are also available at this location under Molina Provider Education Series: Americans with Disabilities Act (ADA), Members who are Blind or have Low Vision, Service Animals and Tips for Communicating with People with Disabilities & Seniors.

The progress related to the goals that Molina Healthcare has set for the annual CAHPS®/QHP Enrollee Experience Survey results and the annual HEDIS® measures can be viewed in more detail on the Molina website. You can also view information about the Quality Improvement Program and print a copy if you would like. Please visit the provider page on Molina's website at MolinaHealthcare.com.

#### Requirements for Submitting Prior Authorization for Molina



Molina requires prior authorization (PA) for specific services. Molina offers three tools on the MolinaHealthcare.com website to assist you in knowing what services require Prior Authorization: The PA Code Matrix, the PA Guide, and the PA Code Lookup Tool. Both the PA Code Matrix and the PA Lookup Tool offer detailed information by CPT and HCPCS code regarding PA requirements. The PA

Code Lookup Tool is conveniently located on the "home" page of the Provider area of <u>MolinaHealthcare.com</u>. Check it out directly <u>here</u>. The most efficient prior authorization submission method is through our Provider Portal at <u>availity.com/molinahealthcare</u>. If you note any discrepancies between the PA Lookup Tool and the PA Code Matrix, reach out to your provider network manager.

When submitting a prior authorization request, be sure to include diagnosis code(s), CPT code(s), requesting provider fax number and billing provider NPI. It is important to include all the clinical information and medical records necessary to support the medical necessity of the requested service/item. The following is an example of documentation needed:

- Current (up to six months) patient history related to the requested service/item
- Relevant physical examination that addresses the medical need for the requested service(s)
- Relevant lab or radiology results to support the request (include previous MRI, CT, lab or X-ray report/results)
- Relevant specialty consultation notes
- Any other information or data specific to the request showing the member meets the criteria for approving the service/item

By providing all necessary clinical information with the initial request, Molina will be able to make a more timely and complete decision based on the member's current health condition while potentially avoiding the need to request additional supporting documentation. The

Urgent/Expedited service request designation should only be used if the treatment is required to prevent serious deterioration in the member's health or could jeopardize their ability to regain maximum function. Requests outside of this definition will be handled as routine/non-urgent. The goal is for Molina to have all necessary information to make the appropriate decision during the initial review of the service/item and avoid the need for an appeal if the service/item is denied.

**NOTE:** In the event a denial is issued, please note the reasons for denial and timeframe provided to either submit new information for re-evaluation or request a peer to peer.

In the event a denial is issued and subsequently appealed, you need to reference the original decision. If the denial was due to missing information needed to justify coverage, not providing that information with your appeal request will not change the decision and could further delay medically necessary covered services/items. Let's work together to ensure timely and appropriate care for your patients.

#### Strengthening the Primary Care Setting with Trauma-Informed Care

Molina Healthcare is dedicated to promoting the importance of Trauma Informed Practice. According to the National Council for Mental Wellbeing, an "individual's experience of trauma impacts every area of human functioning--physical, mental, behavioral, social, and spiritual." Implementing a Trauma Informed care approach in the primary care setting can benefit providers, members, and office staff. The National Council of Mental Wellbeing reports that Trauma-Informed primary care settings can:

- Create safer spaces for staff
- Improve clinical decision-making
- Equip providers to identify and respond to trauma
- Build collaborative care networks to increase provider capacity to address holistic needs

Molina has adopted the guideline for Fostering Resilience and Recovery: A Change Package for Advancing Trauma-Informed Primary Care from The National Council for Mental Wellbeing. For more information, visit Molina's Clinical Program Guidelines on the Molina provider website or visit the National Council for Mental Wellbeing to access the guidelines here.

# Secure Messaging from Claim Status Screen Enabled in Availity Essentials Portal

Molina Healthcare strives to offer tools to provider partners so you can get more done with less effort. Molina now offers an integrated messaging feature from the Claim Status screen in the Availity Essentials portal.

You can submit secure messages from the Claim Status screen directly to Molina using Availity's Messaging Application.

Note: You will need the Claim Status and the Messaging App roles to access this function. If you are an administrator for your organization, you can assign roles by selecting Maintain User from your account dashboard. Then, select the user and View/Edit their roles.

#### Accessing Secure Messaging: Go to Claims & Payments | Claims Status

- 1. Initiate a message via the "Message this payer" option on the claim status results page.
  - **Important:** The message must pertain to the current claim listed on the claim status results page.
- 2. Allow up to two business days for a response.
- 3. Access the Messaging Queue from the top right corner of your Availity home page.
- 4. Conversations display as cards. The color of the cards indicate the status.
- 5. All users have sorting and filtering options. If a message is missing from your queue, clear your filter options

Availity's Messaging App is a faster, more effective platform for resolving simple queries. The next time you have a question about the status of a claim, try messaging.

**Customer Support:** If you have questions about Messaging from Claim Status, you can reach Availity Client Services at (800) 282-4548 from 7 a.m. to 7 p.m. CT, Monday through Friday.

**Additional Questions?** We're here to help. Contact your provider network manager at <u>WIProviderNetworkManagement@MolinaHealthCare.Com</u> or visit: <u>MolinaHealthcare.com</u>.

**Availity Essentials Portal:** We continue our transition to the Availity Essentials Portal, a tool that streamlines your claims management, authorizations, and eligibility/benefit verification. Are you registered? If not, <u>click here</u> to get started.

### Clinician Administered Preferred Drug List 2022

A clinician-administered drug is an outpatient drug other than a vaccine that is typically administered by a health care provider in a clinician's office or other outpatient clinical setting. For example, drugs infused or injected are typically clinician-administered drugs.

The Molina Healthcare, Inc. Medical Preferred Drug List encourages utilization of clinically appropriate and lower net cost products within the following therapeutic drug classes. The Molina Medical Preferred Drug List includes the listed products only. Other products may be available under a plan's medical benefit. The listed preferred products must be used first. An exception process is in place for specific circumstances that may warrant a need for a non-preferred product.

### Medicaid Medical Preferred Drug List- Through October 2022

| Drug Class            | Non-Preferred Product(s)             | Preferred Product(s)           |
|-----------------------|--------------------------------------|--------------------------------|
| Alpha-1 Antitrypsin   | Aralast® (Alpha-1-Proteinase         | Prolastin C®                   |
| Deficiency            | Inhibitor), Glassia® (Alpha-1-       | (Alpha-1-Proteinase Inhibitor) |
|                       | Proteinase Inhibitor), Zemaira®      | ·                              |
|                       | (Alpha-1-Proteinase Inhibitor)       |                                |
| Hematologic, Colony   | Granix <sup>®</sup> (tbo-filgrastum) | Zarxio® (filgrastim-sndz)      |
| Stimulating Factors – | Leukine® (sargramostim)              |                                |
| Short Acting          | Neupogen® (filgrastim)               |                                |
|                       | Nivestym® (filgrastim-aafi)          |                                |

| Hematologic, Colony<br>Stimulating Factors –<br>Long Acting | Fulphila™ (pegfilgrastim-jmdb),<br>Udenyca® (pegfilgrastim-cbqv),<br>Neulasta® (pegfilgrastim)<br>Nyvepria™(pegfilgrastim-apgf)  | Ziextenzo® (pegfilgrastim-bmez)  |
|---|--|--|
| Infliximab  | Remicade <sup>®</sup> (infliximab)   | Inflectra <sup>®</sup> (infliximab-dyyb)<br>Renflexis <sup>®</sup> (infliximab-abda)<br>Avsola™ (infliximab-axxq)  |
| Lysosomal Storage<br>Disorders – Gaucher<br>Disease         | VPRIV <sup>®</sup> (velaglucerase alfa)<br>Elelyso <sup>®</sup> (taliglucerase alfa)   | Cerezyme <sup>®</sup> (imiglucerase)   |
| Multiple Sclerosis (Infused)                                | Lemtrada® (alemtuzumab)  | Tysabri <sup>®</sup> (natalizumab)<br>Ocrevus <sup>®</sup> (ocrelizumab)   |
| Osteoarthritis,<br>Viscosupplements                         | Gelsyn-3® (sodium hyaluronate 8.4mg/ml) GenVisc® 850 (sodium hyaluronate) Hyalgan® (1% sodium hyaluronate) Hymovis® (hyaluronic acid 8mg/ml) Orthovisc® (1% sodium hyaluronate) Supartz® FX (1% sodium hyaluronate) TriVisc®(sodium hyaluronate) Visco-3® (1% sodium hyaluronate) Synvisc® (hylan (Avian) 8 mg/mL) | Euflexxa <sup>®</sup> (1% sodium hyaluronate)  |
| Oncology  | **Avastin <sup>®</sup> (bevacizumab)   | Mvasi™ (bevacizumab-awwb)<br>Zirabev® (bevacizumab-bvzr)   |
|   | Herceptin <sup>®</sup> (trastuzumab)<br>Herceptin Hycelta™<br>(trastuzumab and<br>hyaluronidase-oysk)  | Herzuma <sup>®</sup> (trastuzumab-pkrb)<br>Kanjinti™(trastuzumab-anns)<br>Ogivri™ (trastuzumab-dkst)<br>Ontruzant <sup>®</sup> (trastuzumab-dttb)<br>Trazimera™ (trastuzumab-qyyp) |
| Paroxysmal Nocturnal<br>Hemoglobinuria                      | Ultomiris® (ravulizumab-cwvz)  | Empaveli <sup>®</sup> (pegcetacoplan)  |
| Rituximab   | Rituxan <sup>®</sup> (rituximab)<br>Rituxan Hycela <sup>®</sup> (rituximab-<br>hyaluronidase)  | Truxima <sup>®</sup> (rituximab-abbs)<br>Ruxience <sup>®</sup> (rituximab-pvvr)<br>Riabni™ (rituximab-arrx)  |
| Retinal Disorders (Eye)                                     | Eylea <sup>®</sup> (aflibercept)<br>Lucentis <sup>®</sup> (ranibizumab)  | **Avastin <sup>®</sup> (bevacizumab)   |

# **Marketplace Medical Preferred Drug List- Through October 2022**

| Drug Class   | Non-Preferred Product(s)  | Preferred Product(s)  |
|--|---|---|
| Alpha-1 Antitrypsin<br>Deficiency                            | Aralast <sup>®</sup> (Alpha-1-Proteinase<br>Inhibitor), Glassia <sup>®</sup> (Alpha-1-<br>Proteinase Inhibitor),<br>Zemaira <sup>®</sup> (Alpha-1-<br>Proteinase Inhibitor)   | Prolastin C <sup>®</sup><br>(Alpha-1-Proteinase Inhibitor)  |
| Autoimmune   | Actemra <sup>®</sup> (tocilizumab) IV,<br>Cimzia <sup>®</sup> (certolizumab pegol),<br>Orencia <sup>®</sup> (abatacept)   | Enyvio <sup>®</sup> (vedolizumab),<br>Ilumya™ (tilgrakizumab-asmn),<br>Simoni Aria <sup>®</sup> (golimumab),<br>Stelara <sup>®</sup> (ustekinumab)  |
| Botulinum Toxins   | Myobloc <sup>®</sup> (rimabotulinumtoxin B)   | Botox <sup>®</sup> (onabotulinumtoxin A),<br>Dysport <sup>®</sup> (abobotulinumtoxin A),<br>Xeomin <sup>®</sup> (incobotuliniumtoxin A)   |
| Hematologic, Colony<br>Stimulating Factors –<br>Short Acting | Granix <sup>®</sup> (tbo-filgrastum)<br>Leukine <sup>®</sup> (sargramostim)<br>Neupogen <sup>®</sup> (filgrastim)   | Nivestym <sup>®</sup> (filgrastim-aafi),<br>Zarxio <sup>®</sup> (filgrastim-sndz)   |
| Hematologic, Colony<br>Stimulating Factors –<br>Long Acting  | Fulphila™ (pegfilgrastim-jmdb),<br>Udenyca® (pegfilgrastim-cbqv),<br>Nyvepria™(pegfilgrastim-apgf)  | Ziextenzo <sup>®</sup> (pegfilgrastim-bmez),<br>Neulasta <sup>®</sup> (pegfilgrastim)   |
| Hematologic,<br>Erythropoiesis -<br>Stimulating Agents       | Epogen <sup>®</sup> (epoetin alfa),<br>Mircera <sup>®</sup> (methoxy polyethylene<br>glycol-epoetin beta),<br>Procrit <sup>®</sup> (epoetin alfa)   | Aranesp <sup>®</sup> (darbepoetin),<br>Retacrit <sup>®</sup> (epoetin alfa-epbx)  |
| Hemophilia, Factor VIII                                      | Eloctate <sup>®</sup> (antihemophilic factor recombinant Fc fusion protein), Helixate <sup>®</sup> [Antihemophilic Factor (Recombinant), Formulated with Sucrose], Nuwiq <sup>®</sup> [antihemophilic Factor (recombinant)] | Adynovate <sup>®</sup> [antihemophilic factor (recombinant), PEGylated], Jivi <sup>®</sup> [antihemophilic factor (recombinant), PEGylated], Kogenate <sup>®</sup> [antihemophilic factor (recombinant), Kovaltry <sup>®</sup> [antihemophilic factor (recombinant), Novoeight <sup>®</sup> [antihemophilic factor (recombinant)) |
| Infliximab   | Remicade <sup>®</sup> (infliximab)  | Inflectra <sup>®</sup> (infliximab-dyyb)<br>Renflexis <sup>®</sup> (infliximab-abda)<br>Avsola™ (infliximab-axxq)   |
| Long-Acting<br>Reversible<br>Contraceptives                  | Liletta <sup>®</sup> (levonorgestrel-releasing intrauterine system) Nexplanon <sup>®</sup> (etonogestrel implant)   | Kyleena <sup>®</sup> (levonorgestrel-<br>releasing intrauterine system),<br>Mirena <sup>®</sup> (levonorgestrel-releasing<br>intrauterine system)<br>Skyla <sup>®</sup> (levonorgestrel-releasing<br>intrauterine system)   |
| Lysosomal Storage<br>Disorders – Gaucher<br>Disease          | VPRIV <sup>®</sup> (velaglucerase alfa)<br>Cerezyme <sup>®</sup> (imiglucerase)   | Elelyso <sup>®</sup> (taliglucerase alfa)   |

| Multiple Sclerosis                    | Lemtrada® (alemtuzumab)                   | Tysabri <sup>®</sup> (natalizumab)     |
|---------------------------------------|---|--|
| (Infused)                             |   | Ocrevus® (ocrelizumab)                 |
| Osteoarthritis,                       | Gelsyn-3 <sup>®</sup> (sodium hyaluronate | Euflexxa® (1% sodium                   |
| Viscosupplements                      | 8.4mg/ml)                                 | hyaluronate)                           |
|                                       | GenVisc® 850 (sodium                      | Orthovisc® (1% sodium                  |
|                                       | hyaluronate) `                            | hyaluronate)                           |
|                                       | Hyalgan® (1 <sup>′</sup> % sodium         | Monovisc® ( sodium hyaluronate)        |
|                                       | hyaluronate)                              | , , ,                                  |
|                                       | Hymovis® (hyaluronic acid                 |  |
|                                       | 8mg/ml)                                   |  |
|                                       | Supartz <sup>®</sup> FX (1% sodium        |  |
|                                       | hyaluronate) `                            |  |
|                                       | TriVisc®(sodium hyaluronate)              |  |
|                                       | Visco-3 <sup>®</sup> (1% sodium           |  |
|                                       | hyaluronate)                              |  |
|                                       | Synvisc <sup>®</sup> (hylan (Avian) 8     |  |
|                                       | mg/mL)                                    |  |
| Oncology                              | NA /                                      | Firmagon® (degarelix)                  |
| · · · · · · · · · · · · · · · · · · · | **Avastin® (bevacizumab)                  | Mvasi™ (bevacizumab-awwb)              |
|                                       | (**************************************   | Zirabev® (bevacizumab-bvzr)            |
|                                       | Herceptin <sup>®</sup> (trastuzumab)      | Kanjinti™(trastuzumab-anns)            |
|                                       | Herzuma <sup>®</sup> (trastuzumab-pkrb)   | Ogivri™ (trastuzumab-dkst) ´           |
|                                       | Herceptin Hycelta™                        | (" " " " " " " " " " " " " " " " " " " |
|                                       | (trastuzumab and hyaluronidase-           |  |
|                                       | oysk)                                     |  |
|                                       | Trazimera™ (trastuzumab-qyyp)             |  |
|                                       | Ontruzant® (trastuzumab-dttb)             |  |
| Paroxysmal Nocturnal                  | Ultomiris® (ravulizumab-cwvz)             | Empaveli® (pegcetacoplan)              |
| Hemoglobinuria                        | (   |  |
| Retinal Disorder                      | Eylea®(aflibercept)                       | **Avastin <sup>®</sup> (bevacizumab)   |
| Agents (Eye)                          | Lucentis® (ranibizumab)                   | (22121111111)                          |
| Rituximab                             | Rituxan® (rituximab)                      | Truxima®(rituximab-abbs)               |
|                                       | Rituxan Hycela®(rituximab-                | Ruxience <sup>®</sup> (rituximab-pvvr) |
|                                       | hyaluronidase) `                          | Riabni™ (rituximab-arrx) ´             |
| Severe Asthma                         | Cinqair® (reslizumab)                     | Dupixent®(dupilumab)                   |
|                                       |   | Fasenra®(benralizumab)                 |
|                                       |   | Nucala <sup>®</sup> (mepolizumab)      |
|                                       |   | Xolair® (omalizumab)                   |
|                                       |   | (55)                                   |